Press Releases
Flamel Technologies Announces the Resignation of Jean Deleage as a Board Member
Lyon, France, August 24, 2001 - Flamel Technologies (NASDAQ:FLML) announced today the resignation of Jean Deleage as a member of the board of directors of the company. After serving for eleven years as a member of the board, and as an initial venture capital investor in the Company, Mr. Deleage is resigning, effective immediately, to focus additional time on other boards of directors on which he serves.
Dr. Gerard Soula, president and chief executive officer of Flamel, said: “Jean Deleage was a cofounder of Flamel at its inception and we are extremely grateful for his eleven years of service to our Company. Various funds affiliated with Mr. Deleage continue to hold a substantial portion of the Flamel’s shares and we look forward to the continued advice and insights of Mr. Deleage as we move forward as a company".
Flamel Technologies S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel’s Medusa® nano-encapsulation technology is designed to deliver therapeutic proteins. Micropump® is a controlled release technology for the oral administration of small molecule drugs. Flamel’s expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product now marketed by Corning Inc. Additionally, Flamel has developed new herbicide delivery systems now being tested by Monsanto and has patented a biomaterial, ColCys™.
This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel’s reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel’s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 1999.
